Progress of KRASG12C mutations in non-small cell lung cancer

doi:10.3760/cma.j.cn371439-20231008-00013

Abstract

Abstract:

With the continuous in-depth research on the mechanism of KRAS^G12Cmutations in targeted therapy of non-small cell lung cancer，KRAS^G12C has evolved from non producible to an important targeted therapy site. The KRAS^G12C mutation inhibitor has achieved dual progress in efficiency and survival in targeted therapy of non-small cell lung cancer. Although drug resistance is inevitable with treatment，research on drug resistance mechanisms has found that combination medication is one of the ways to overcome or reduce drug resistance.

Key words: KRAS, Carcinoma, non-small-cell lung, Molecular targeted therapies

Ma Zhenghong, Jiang Chao. Progress of KRAS^G12C mutations in non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(2): 95-98.

References 38

[1]	Liu P, Wang Y, Xin L. Targeting the untargetable KRAS in cancer therapy[J]. Acta Pharm Sin B, 2019, 9(5): 871-879. DOI: 10.1016/j.apsb.2019.03.002. pmid: 31649840
[2]	Timar J, Kashofer K. Molecular epidemiology and diagnostics of KRAS mutations in human cancer[J]. Cancer Metastasis Rev, 2020, 39(4): 1029-1038. DOI: 10.1007/s10555-020-09915-5.
[3]	Judd J, Abdel Karim N, Khan H, et al. Characterization of KRAS mutation subtypes in non-small cell lung cancer[J]. Mol Cancer Ther, 2021, 20(12): 2577-2584. DOI: 10.1158/1535-7163.MCT-21-0201. pmid: 34518295
[4]	Ricciuti B, Alessi JV, Elkrief A, et al. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS^G12D-mutated non-small-cell lung cancer[J]. Ann Oncol, 2022, 33(10): 1029-1040. DOI: 10.1016/j.annonc.2022.07.005. pmid: 35872166
[5]	Negrao MV, Araujo HA, Lamberti G, et al. Comutations and KRAS^G12C inhibitor efficacy in advanced NSCLC[J]. Cancer Discov, 2023, 13(7): 1556-1571. DOI: 10.1158/2159-8290.CD-22-1420.
[6]	Sebastian M, Eberhardt WEE, Hoffknecht P, et al. KRAS^G12C-mutated advanced non-small cell lung cancer: a real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)[J]. Lung Cancer, 2021, 154: 51-61. DOI: 10.1016/j.lungcan.2021.02.005. pmid: 33611226
[7]	Cui W, Franchini F, Alexander M, et al. Real world outcomes in KRAS^G12C mutation positive non-small cell lung cancer[J]. Lung Cancer, 2020, 146: 310-317. DOI: 10.1016/j.lungcan.2020.06.030.
[8]	Wu MY, Zhang EW, Strickland MR, et al. Clinical and imaging features of non-small cell lung cancer with G12C KRAS mutation[J]. Cancers (Basel), 2021, 13(14): 3572. DOI: 10.3390/cancers13143572.
[9]	Reck M, Carbone DP, Garassino M, et al. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches[J]. Ann Oncol, 2021, 32(9): 1101-1110. DOI: 10.1016/j.annonc.2021.06.001. pmid: 34089836
[10]	Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRAS^G12C somatic mutations across race, sex, and cancer type[J]. N Engl J Med, 2021, 384(2): 185-187. DOI: 10.1056/NEJMc2030638.
[11]	Ou SI, Jänne PA, Leal TA, et al. First-in-human phase Ⅰ/ⅠB dose-finding study of adagrasib (MRTX849) in patients with advanced KRAS^G12C solid tumors (KRYSTAL-1)[J]. J Clin Oncol, 2022, 40(23): 2530-2538. DOI: 10.1200/JCO.21.02752.
[12]	Arbour KC, Rizvi H, Plodkowski AJ, et al. Treatment outcomes and clinical characteristics of patients with KRAS-G12C-mutant non-small cell lung cancer[J]. Clin Cancer Res, 2021, 27(8): 2209-2215. DOI: 10.1158/1078-0432.CCR-20-4023. pmid: 33558425
[13]	Hong DS, Fakih MG, Strickler JH, et al. KRAS^G12C inhibition with sotorasib in advanced solid tumors[J]. N Engl J Med, 2020, 383(13): 1207-1217. DOI: 10.1056/NEJMoa1917239.
[14]	Ferdinandos S, Bob TL, Dy GK, et al. Sotorasib for lung cancers with KRAS p.G12C mutation[J]. N Engl J Med, 2021, 384(25): 2371-2381. DOI: 10.1056/NEJMoa2103695.
[15]	Xue JY, Zhao Y, Aronowitz J, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition[J]. Nature, 2020, 577(7790): 421-425. DOI: 10.1038/s41586-019-1884-x.
[16]	Koster KL, Appenzeller C, Lauber A, et al. Sotorasib shows intracranial activity in patients with KRAS^G12C-mutated adenocarcinoma of the lung and untreated active brain metastases[J]. Case Rep Oncol, 2022, 15(2): 720-725. DOI: 10.1159/000525341.
[17]	Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions[J]. Nature, 2013, 503(7477): 548-551. DOI: 10.1038/nature12796.
[18]	O'Bryan JP. Pharmacological targeting of RAS: recent success with direct inhibitors[J]. Pharmacol Res, 2019, 139: 503-511. DOI: 10.1016/j.phrs.2018.10.021. pmid: 30366101
[19]	Hallin J, Engstrom LD, Hargis L, et al. The KRAS^G12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients[J]. Cancer Discov, 2020, 10(1): 54-71. DOI: 10.1158/2159-8290.CD-19-1167. pmid: 31658955
[20]	Grace KD, Ramaswamy G, Vamsidhar V, et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100[J]. J Clin Oncol, 2023, 41(18): 3311-3317. DOI: 10.1200/JCO.22.02524.
[21]	Brazel D, Kim J, Ou SI. CodeBreaK 200: sotorasib (AMG510) has broken the KRAS G12C⁺ NSCLC enigma code[J]. Lung Cancer (Auckl), 2023, 14: 31-39. DOI: 10.2147/LCTT.S403614.
[22]	Isaksson J, Berglund A, Louie K, et al. KRAS^G12C mutant non-small cell lung cancer linked to female sex and high risk of CNS metastasis: population-based demographics and survival data from the National Swedish Lung Cancer Registry[J]. Clin Lung Cancer, 2023, 24(6): 507-518. DOI: 10.1016/j.cllc.2023.05.002. pmid: 37296038
[23]	Sabari JK, Velcheti V, Shimizu K, et al. Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRAS^G12C-mutant non-small cell lung cancer[J]. Clin Cancer Res, 2022, 28(15): 3318-3328. DOI: 10.1158/1078-0432.CCR-22-0383. pmid: 35404402
[24]	Negrao MV, Spira AI, Heist RS, et al. Intracranial efficacy of adagrasib in patients from the KRYSTAL-1 trial with KRAS^G12C-mutated non-small-cell lung cancer who have untreated CNS metastases[J]. J Clin Oncol, 2023, 41(28): 4472-4477. DOI: 10.1200/JCO.23.00046.
[25]	Zhang J, Johnson M, Barve M, et al. Practical guidance for the management of adverse events in patients with KRAS^G12C-mutated non-small cell lung cancer receiving adagrasib[J]. Oncologist, 2023, 28(4): 287-296. DOI: 10.1093/oncolo/oyad051. pmid: 36892150
[26]	Bekaii-Saab TS, Yaeger R, Spira AI, et al. Adagrasib in advanced solid tumors harboring a KRAS^G12C mutation[J]. J Clin Oncol, 2023, 41(25): 4097-4106. DOI: 10.1200/JCO.23.00434.
[27]	Zhao Y, Murciano-Goroff YR, Xue JY, et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition[J]. Nature, 2021, 599(7886): 679-683. DOI: 10.1038/s41586-021-04065-2.
[28]	Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity[J]. Nature, 2019, 575(7781): 217-223. DOI: 10.1038/s41586-019-1694-1.
[29]	Pantsar T. KRAS(G12C)-AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations[J]. Sci Rep, 2020, 10(1): 11992. DOI: 10.1038/s41598-020-68950-y.
[30]	Koga T, Suda K, Fujino T, et al. KRAS secondary mutations that confer acquired resistance to KRAS^G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments[J]. J Thorac Oncol, 2021, 16(8): 1321-1332. DOI: 10.1016/j.jtho.2021.04.015.
[31]	Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival[J]. Cancer Cell, 2021, 39(3): 441-442. DOI: 10.1016/j.ccell.2021.02.009.
[32]	Awad MM, Liu S, Rybkin II, et al. Acquired resistance to KRAS^G12C inhibition in cancer[J]. N Engl J Med, 2021, 384(25): 2382-2393. DOI: 10.1056/NEJMoa2105281.
[33]	Amodio V, Yaeger R, Arcella P, et al. EGFR blockade reverts resistance to KRAS^G12C inhibition in colorectal cancer[J]. Cancer Discov, 2020, 10(8): 1129-1139. DOI: 10.1158/2159-8290.CD-20-0187. pmid: 32430388
[34]	Yaeger R, Mezzadra R, Sinopoli J, et al. Molecular characterization of acquired resistance to KRAS^G12C-EGFR inhibition in colorectal cancer[J]. Cancer Discov, 2023, 13(1): 41-55. DOI: 10.1158/2159-8290.CD-22-0405.
[35]	Zhang SS, Nagasaka M. Spotlight on sotorasib (AMG 510) for KRAS^G12C positive non-small cell lung cancer[J]. Lung Cancer (Auckl), 2021, 12: 115-122. DOI: 10.2147/LCTT.S334623.
[36]	Christofyllakis K, Monteiro AR, Cetin O, et al. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: a young International Society of Geriatric Oncology report[J]. J Geriatr Oncol, 2022, 13(8): 1071-1083. DOI: 10.1016/j.jgo.2022.04.013. pmid: 35525790
[37]	Brown WS, McDonald PC, Nemirovsky O, et al. Overcoming adaptive resistance to KRAS and MEK inhibitors by co-targeting mTORC1/2 complexes in pancreatic cancer[J]. Cell Rep Med, 2020, 1(8): 100131. DOI: 10.1016/j.xcrm.2020.100131.
[38]	Hamarsheh S, Groß O, Brummer T, et al. Immune modulatory effects of oncogenic KRAS in cancer[J]. Nat Commun, 2020, 11(1): 5439. DOI: 10.1038/s41467-020-19288-6. pmid: 33116132

Progress of KRAS^G12C mutations in non-small cell lung cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 38

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[3]	Wang Kun, Zhou Zhongxin, Zang Qiwei. Predictive value of serum TGF-β1 and VEGF levels in patients with non-small cell lung cancer after single-port thoracoscopic radical resection [J]. Journal of International Oncology, 2024, 51(4): 198-203.
[4]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[5]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[6]	Yan Aiting, Wang Cuizhu, Liu Chungui, Lu Xiaomin. Clinical efficacy and safety of camrelizumab and sintilimab in the treatment of advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 137-142.
[7]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[8]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[9]	Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng. Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinoma in situ of the breast [J]. Journal of International Oncology, 2024, 51(3): 166-169.
[10]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[11]	Liu Bohan, Huang Junxing. Research progress of liquid biopsy technology in esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(2): 105-108.
[12]	Li Dan, Li Ruiyao, Li Yinghan, Yu Xiuyan, Wu Xuefeng. Clinical value of serum miR-19b and miR-744-5p levels in the diagnosis of non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(2): 83-88.
[13]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie. Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(2): 89-94.
[14]	Zhang Keping, Zhao Yongsheng, Yang Juan, Fu Maoyong. Chlorogenic acid induces mitochondrial dysfunction in lung cancer A549 cells by inhibiting the PI3K-Akt pathway [J]. Journal of International Oncology, 2024, 51(1): 21-28.
[15]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.